ReviewZhongguo fei ai za zhi = Chinese journal of lung cancer2026
[Advances on Postoperative Recurrence Risk Prediction in Non-small Cell Lung Cancer].
Review in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer remains the malignant tumor with the highest incidence and mortality rates worldwide, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of cases. Radical surgical resection serves as the primary curative modality for patients with resectable NSCLC; however, postoperative recurrence persists in a subset of patients, thereby compromising long-term survival outcomes. Consequently, the precise prediction of postoperative recurrence risk, identification of high-risk populations, and formulation of individualized adjuvant therapy and surveillance strategies are of paramount importance for improving patient prognosis. In recent years, fueled by the rapid evolution of artificial intelligence (AI) and liquid biopsy technologies, the prediction of postoperative recurrence in NSCLC has progressively transitioned toward greater precision and personalization. This review summarizes the current applications of traditional predictive models, AI-based models, and liquid biopsy techniques in forecasting NSCLC recurrence following surgery, evaluating their respective strengths and limitations. Furthermore, it provides insights into future research trajectories. .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.